Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

PAI-1 Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:Plasminogen activator inhibitor 1, Endothelial plasminogen activator inhibitor, Serpine 1, PAI, PLANH-1
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


RAF083R 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Sandwich ELISA, Biotin-labelled antibody

Applications

Serum, Plasma-EDTA, Plasma-Heparin, Plasma-Citrate, Cell culture supernatant

Sample Requirements

50 µl (1:50 prediluted)

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

78–5000 pg/ml

Limit of Detection

29 pg/ml

Intra-assay (Within-Run)

CV = 4.7%

Inter-assay (Run-to-Run)

CV = 5.0%

Spiking Recovery

58,70%

Dilution Linearity

98,70%

Summary

Research topic

Energy metabolism and body weight regulation, Others

Summary

Plasminogen activator inhibitor-1 (PAI-1) is the primary inhibitor of plasminogen activators in plasma, rapidly inactivating both tissue plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA). PAI-1 is a single-chain glycoprotein with a molecular weight of 47 kilodaltons. During fibrinolysis, tissue plasminogen activator (tPA) converts the inactive protein plasminogen into plasmin which plays a critical role in fibrinolysis by degrading fibrin and providing localized protease activity in a number of physiological functions. PAI-1 is synthesized in the liver and by endothelial cells, and its synthesis is regulated by several physiologic mediators, including endotoxin, interleukin-1, fibroblast growth factor-2, and lipids. Plasminogen activator inhibitor-1 is an important inhibitor of the fibrinolytic system, so elevated levels could suppress fibrinolysis and result in an increased risk of thrombosis. Increased PAI-1 levels have been shown to be associated with a number of atherosclerotic risk factors, PAI-1 has been shown to act as a prothrombic factor in both arterial and venous thromboembolic disorders. Increased levels of PAI-1 are associated with an increased incidence of acute coronary syndrome. PAI-1 levels are also increased in patients with chronic and acute coronary artery disease (CAD) and in patients who suffer restenosis after coronary angioplasty.

Product References (2)

References

  • Gurbuz Y, Ozturk B, Tutuncu EE, Sencan I, Cicek Senturk G, Altay FA.Evaluation of Prognostic Values of Tissue Plasminogen Activator and PlasminogenActivator Inhibitor-1 in Crimean-Congo Hemorrhagic Fever Patients. Jundishapur J Microbiol. 2015 Oct 20;8(10):e26514. doi: 10.5812/jjm.26514. eCollection 2015Oct. PubMed PMID: 26587219; PubMed Central PMCID: PMC4644349. See more on PubMed
  • Kuwano T. [Problems in nursing of patients in the terminal stage - impressionson the conference record of a suicide patient]. Kango Gijutsu. 1978Mar;24(4):178-81. Japanese. PubMed PMID: 246073. See more on PubMed
Summary References (8)

References to PAI-1

  • Adcock DM, Kressin DC, Marlar RA. Effect of 3.2% vs 3.8% sodium citrate concentration on routine coagulation testing. Am J Clin Pathol. 1997 Jan;107 (1):105-10
  • Gottfried EL, Adachi MM. Prothrombin time and activated partial thromboplastin time can be performed on the first tube. Am J Clin Pathol. 1997 Jun;107 (6):681-3
  • Huber K. Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease. J Thromb Thrombolysis. 2001 May;11 (3):183-93
  • Huber K. Plasminogen activator inhibitor type-1 (part two): role for failure of thrombolytic therapy. PAI-1 resistance as a potential benefit for new fibrinolytic agents. J Thromb Thrombolysis. 2001 May;11 (3):195-202
  • Huber K, Christ G, Wojta J, Gulba D. Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001. Thromb Res. 2001 Sep 30;103 Suppl 1:S7-19
  • McGlasson DL, More L, Best HA, Norris WL, Doe RH, Ray H. Drawing specimens for coagulation testing: is a second tube necessary?. Clin Lab Sci. 1999 May-Jun;12 (3):137-9
  • National Committee for Clinical Laboratory Standardization. Collection, Transport, and Processing of Blood Specimens for Coagulation Testing and General Performance of Coagulation Assays; Approved Guideline. Third Edition, Villanova: NCCL. 1999;H21-A3:11(23)
  • Reneke J, Etzell J, Leslie S, Ng VL, Gottfried EL. Prolonged prothrombin time and activated partial thromboplastin time due to underfilled specimen tubes with 109 mmol/L (3.2%) citrate anticoagulant. Am J Clin Pathol. 1998 Jun;109 (6):754-7
Related Products Docs